Company profile: Tandem Diabetes Care
1.1 - Company Overview
Company description
- Provider of insulin delivery solutions including the t:slim X2 insulin pump with color touchscreen that pairs with multiple CGM sensors and uses Control-IQ technology for automated insulin delivery; the Tandem Mobi System, a compact pump controllable via a compatible iPhone; Control-IQ Technology adjusting insulin based on CGM readings with automatic correction boluses and activity settings; infusion sets; and remote software updates.
Products and services
- Control-IQ Technology: Automated system that adjusts insulin delivery using CGM sensor readings, delivering automatic correction boluses and configurable activity settings to manage glucose levels
- T:slim X2 Insulin Pump: CGM-integrated pump with color touchscreen pairs with multiple CGM sensors, using Control-IQ technology for automated insulin delivery and automatic correction boluses to manage glucose levels
- Tandem Mobi System: Compact insulin pump that can be worn in various ways and controlled via a compatible iPhone, utilizing Control-IQ technology for automated insulin delivery and configurable activity settings
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tandem Diabetes Care
Home Diagnostics
HQ: United States
Website
- Description: Provider of blood glucose monitoring systems and disposable supplies for diabetics, developed, manufactured and marketed by Home Diagnostics, offering performance and features comparable to or better than competitors' products, in most cases at a substantially lower price.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Home Diagnostics company profile →
SFC Fluidics
HQ: United States
Website
- Description: Provider of microfluidic-enabled medical devices, including the Gemini Dual Hormone Artificial Pancreas Pod, a wearable system delivering insulin and glucagon for diabetes management; the Panda Insulin Delivery Pod, a disposable subcutaneous insulin pump with precise dosing; and the Min-ePump, an implantable device for small animal research enabling remote-controlled, real-time drug dosing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SFC Fluidics company profile →
Dexcom
HQ: United States
Website
- Description: Provider of continuous glucose monitoring systems and data services for diabetes management, developing, manufacturing and distributing Dexcom G7 (real-time readings and alerts, compatible with Apple Watch), Dexcom G6 (for users 2+), and the OTC Stelo Glucose Biosensor System for adults not on insulin, plus Dexcom Clarity for glucose data analysis and Dexcom Follow/Share for remote data sharing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dexcom company profile →
TheraSense
HQ: United States
Website
- Description: Provider of easy-to-use glucose self-monitoring systems for people with diabetes, using proprietary technologies to dramatically reduce the pain of testing. Products are less painful than current offerings; FreeStyle, the first product, accurately measures glucose levels in blood.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TheraSense company profile →
Diabeloop
HQ: France
Website
- Description: Provider of automated insulin delivery and diabetes management solutions, developing closed-loop systems to automate treatment of type 1 diabetes, including DBLG1, an algorithm-driven system; DBL-hu for highly unstable type 1 diabetes; and DBL-4pen, a smartphone app with an auto-learning algorithm linked to a connected insulin pen and CGM.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diabeloop company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tandem Diabetes Care
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tandem Diabetes Care
2.2 - Growth funds investing in similar companies to Tandem Diabetes Care
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tandem Diabetes Care
4.2 - Public trading comparable groups for Tandem Diabetes Care
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →